Pre-made Blinatumomab benchmark antibody ( Bispecific T-Cell Engager, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-074
Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody|
|Format||Bispecific T-Cell Engager|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Companies||Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis|
|Conditions Approved||Precursor B-cell lymphoblastic leukaemia-lymphoma|
|Conditions Active||Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma|
|Conditions Discontinued||Chronic lymphocytic leukaemia|
|Development Tech||BiTE Technology|